Radiation Therapy Has Delayed Cancer Treatment Changes
A clinical trial found that targeted radiation helped patients with metastatic breast cancer stay on their current therapy.
Updated on Oct. 5, 2026 in Cancer
Live Poll
Do you prefer cancer treatments that extend current therapies over those that switch medications sooner?
A new clinical trial has demonstrated that stereotactic body radiation therapy (SBRT) can help patients with ER-positive metastatic breast cancer maintain their current treatment regimen. Among the initial group of eight study participants, half successfully remained on their systemic therapy for at least six months after receiving the targeted radiation.
Why it matters
This approach explores whether ablating progressing lesions can delay the need to switch systemic medications, which could improve quality of life and treatment efficacy. By extending the duration of current therapies, the study seeks to optimize how metastatic disease is managed for eligible patients.
In a Simon two-stage trial, 4 of the first 8 patients with ER-positive metastatic breast cancer remained on their systemic therapy for 6 months post-SBRT. These preliminary findings met the threshold required to expand the trial, which is currently enrolling a maximum of 18 patients.
The details
The trial strategy involves using SBRT to precisely ablate all progressing lesions in patients who have received up to three lines of systemic therapy. Researchers utilize FES PET imaging to monitor estrogen receptor activity, allowing them to target specific areas of disease progression. This localized approach aims to manage tumor growth while potentially preventing or delaying the physical toll of switching systemic medications.
Timeline
Participants must remain on systemic therapy for 6 months post-SBRT to meet the primary outcome.
Health Landscape
This trial aligns with ongoing efforts to integrate local ablation strategies into the standard of care for metastatic disease. It represents a potential shift toward precision-based maintenance of systemic therapies in the evolving treatment landscape for ER-positive breast cancer.
If you are managing ER-positive metastatic breast cancer, consider discussing with your oncologist whether local ablation therapies could play a role in your current treatment plan. These findings suggest that targeting specific progressing lesions may be a viable strategy to prolong your current therapy.
The takeaway
Targeted radiation therapy may offer a way to stabilize metastatic disease and extend the utility of existing medication regimens. Patients should consult their care team about whether their specific disease progression and therapy line make them candidates for clinical trials involving SBRT.
Further reading
Learn more about the latest innovations in Cancer treatment and research.
Live Poll
Do you prefer cancer treatments that extend current therapies over those that switch medications sooner?
